Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services
Over the last two months, both MatTek and Visikol have been acquired by CELLINK, the world’s leading bioconvergence company. CELLINK is focused on bringing together, the technologies, products, services, and people required to create the future of medicine. Together, MatTek and Visikol bring significant experience with providing researchers best-in-class in vitro models and services for evaluating the safety, efficacy and pharmacokinetics of therapeutics and personal care products. Today, the two companies are announcing that Visikol will now be leveraging the MatTek portfolio of advanced